Brimonidine reduces TGF-beta-induced extracellular matrix synthesis in human Tenon's fibroblasts Glaucoma

Samin Hong, Sueng Han Han, chanyun kim, Kang Yoon Kim, Yoo Kyung Song, Gong Je Seong

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Background: Brimonidine is a highly selective α2 adrenergic agonist that has been widely used in anti-glaucoma eyedrops. The aim of this study was to investigate its putative anti-fibrotic role in the fibrosis caused by activated Tenon's fibroblasts. Methods: Primary cultured human Tenon's fibroblasts were exposed to 2.0 ng/mL of transforming growth factor-β1 (TGF-β1) for up to 48 h. In the presence of various concentrations of brimonidine (from 0.0 to 10.0 μM), the expression levels of fibronectin, collagen types I and III, and β-actin were determined by Western immunoblots. The expression of phosphorylated SMAD2/3 (p-SMAD2/3) was then evaluated using immunofluorescence. Results: TGF-β1 significantly increased the synthesis of fibronectin and collagens in human Tenon's fibroblasts; however brimonidine treatment distinctly attenuated the TGF-β1-induced production of extracellular matrix (ECM) proteins. TGF-β1 also changed the cellular morphology to be plump, while brimonidine treatment returned the cells to a spindle shape, similar to control fibroblasts. Regarding p-SMAD2/3, brimonidine treatment did not show any apparent changes in its expression. Conclusions: Our data revealed that brimonidine reduces TGF-β-induced ECM synthesis in human Tenon's fibroblasts in vitro. This finding implies that topical administration of brimonidine may be helpful in reducing the fibrosis caused by the long-term use of topical anti-glaucoma medications.

Original languageEnglish
Article number54
JournalBMC Ophthalmology
Volume15
Issue number1
DOIs
Publication statusPublished - 2015 May 28

Fingerprint

Transforming Growth Factor beta
Glaucoma
Extracellular Matrix
Fibroblasts
Transforming Growth Factors
Fibronectins
Fibrosis
Topical Administration
Adrenergic Agonists
Collagen Type III
Ophthalmic Solutions
Extracellular Matrix Proteins
Collagen Type I
Brimonidine Tartrate
Fluorescent Antibody Technique
Actins
Collagen
Therapeutics
Western Blotting

All Science Journal Classification (ASJC) codes

  • Ophthalmology

Cite this

Hong, Samin ; Han, Sueng Han ; kim, chanyun ; Kim, Kang Yoon ; Song, Yoo Kyung ; Seong, Gong Je. / Brimonidine reduces TGF-beta-induced extracellular matrix synthesis in human Tenon's fibroblasts Glaucoma. In: BMC Ophthalmology. 2015 ; Vol. 15, No. 1.
@article{0a6c8b42cc1149699aff576e01a407b1,
title = "Brimonidine reduces TGF-beta-induced extracellular matrix synthesis in human Tenon's fibroblasts Glaucoma",
abstract = "Background: Brimonidine is a highly selective α2 adrenergic agonist that has been widely used in anti-glaucoma eyedrops. The aim of this study was to investigate its putative anti-fibrotic role in the fibrosis caused by activated Tenon's fibroblasts. Methods: Primary cultured human Tenon's fibroblasts were exposed to 2.0 ng/mL of transforming growth factor-β1 (TGF-β1) for up to 48 h. In the presence of various concentrations of brimonidine (from 0.0 to 10.0 μM), the expression levels of fibronectin, collagen types I and III, and β-actin were determined by Western immunoblots. The expression of phosphorylated SMAD2/3 (p-SMAD2/3) was then evaluated using immunofluorescence. Results: TGF-β1 significantly increased the synthesis of fibronectin and collagens in human Tenon's fibroblasts; however brimonidine treatment distinctly attenuated the TGF-β1-induced production of extracellular matrix (ECM) proteins. TGF-β1 also changed the cellular morphology to be plump, while brimonidine treatment returned the cells to a spindle shape, similar to control fibroblasts. Regarding p-SMAD2/3, brimonidine treatment did not show any apparent changes in its expression. Conclusions: Our data revealed that brimonidine reduces TGF-β-induced ECM synthesis in human Tenon's fibroblasts in vitro. This finding implies that topical administration of brimonidine may be helpful in reducing the fibrosis caused by the long-term use of topical anti-glaucoma medications.",
author = "Samin Hong and Han, {Sueng Han} and chanyun kim and Kim, {Kang Yoon} and Song, {Yoo Kyung} and Seong, {Gong Je}",
year = "2015",
month = "5",
day = "28",
doi = "10.1186/s12886-015-0045-8",
language = "English",
volume = "15",
journal = "BMC Ophthalmology",
issn = "1471-2415",
publisher = "BioMed Central",
number = "1",

}

Brimonidine reduces TGF-beta-induced extracellular matrix synthesis in human Tenon's fibroblasts Glaucoma. / Hong, Samin; Han, Sueng Han; kim, chanyun; Kim, Kang Yoon; Song, Yoo Kyung; Seong, Gong Je.

In: BMC Ophthalmology, Vol. 15, No. 1, 54, 28.05.2015.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Brimonidine reduces TGF-beta-induced extracellular matrix synthesis in human Tenon's fibroblasts Glaucoma

AU - Hong, Samin

AU - Han, Sueng Han

AU - kim, chanyun

AU - Kim, Kang Yoon

AU - Song, Yoo Kyung

AU - Seong, Gong Je

PY - 2015/5/28

Y1 - 2015/5/28

N2 - Background: Brimonidine is a highly selective α2 adrenergic agonist that has been widely used in anti-glaucoma eyedrops. The aim of this study was to investigate its putative anti-fibrotic role in the fibrosis caused by activated Tenon's fibroblasts. Methods: Primary cultured human Tenon's fibroblasts were exposed to 2.0 ng/mL of transforming growth factor-β1 (TGF-β1) for up to 48 h. In the presence of various concentrations of brimonidine (from 0.0 to 10.0 μM), the expression levels of fibronectin, collagen types I and III, and β-actin were determined by Western immunoblots. The expression of phosphorylated SMAD2/3 (p-SMAD2/3) was then evaluated using immunofluorescence. Results: TGF-β1 significantly increased the synthesis of fibronectin and collagens in human Tenon's fibroblasts; however brimonidine treatment distinctly attenuated the TGF-β1-induced production of extracellular matrix (ECM) proteins. TGF-β1 also changed the cellular morphology to be plump, while brimonidine treatment returned the cells to a spindle shape, similar to control fibroblasts. Regarding p-SMAD2/3, brimonidine treatment did not show any apparent changes in its expression. Conclusions: Our data revealed that brimonidine reduces TGF-β-induced ECM synthesis in human Tenon's fibroblasts in vitro. This finding implies that topical administration of brimonidine may be helpful in reducing the fibrosis caused by the long-term use of topical anti-glaucoma medications.

AB - Background: Brimonidine is a highly selective α2 adrenergic agonist that has been widely used in anti-glaucoma eyedrops. The aim of this study was to investigate its putative anti-fibrotic role in the fibrosis caused by activated Tenon's fibroblasts. Methods: Primary cultured human Tenon's fibroblasts were exposed to 2.0 ng/mL of transforming growth factor-β1 (TGF-β1) for up to 48 h. In the presence of various concentrations of brimonidine (from 0.0 to 10.0 μM), the expression levels of fibronectin, collagen types I and III, and β-actin were determined by Western immunoblots. The expression of phosphorylated SMAD2/3 (p-SMAD2/3) was then evaluated using immunofluorescence. Results: TGF-β1 significantly increased the synthesis of fibronectin and collagens in human Tenon's fibroblasts; however brimonidine treatment distinctly attenuated the TGF-β1-induced production of extracellular matrix (ECM) proteins. TGF-β1 also changed the cellular morphology to be plump, while brimonidine treatment returned the cells to a spindle shape, similar to control fibroblasts. Regarding p-SMAD2/3, brimonidine treatment did not show any apparent changes in its expression. Conclusions: Our data revealed that brimonidine reduces TGF-β-induced ECM synthesis in human Tenon's fibroblasts in vitro. This finding implies that topical administration of brimonidine may be helpful in reducing the fibrosis caused by the long-term use of topical anti-glaucoma medications.

UR - http://www.scopus.com/inward/record.url?scp=84934873349&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84934873349&partnerID=8YFLogxK

U2 - 10.1186/s12886-015-0045-8

DO - 10.1186/s12886-015-0045-8

M3 - Article

C2 - 26017119

AN - SCOPUS:84934873349

VL - 15

JO - BMC Ophthalmology

JF - BMC Ophthalmology

SN - 1471-2415

IS - 1

M1 - 54

ER -